Ahmad Hanif, BS, PhD

Assistant Professor

Organization:

West Virginia University School of Pharmacy

Department:

Pharmaceutical Sciences

Classification:

Faculty

• PhD, West Virginia Univeristy, 2016

1. Hanif, A. M., Edin, M. L., Zeldin, D. C., Morisseau, C., & Nayeem, M. A. (2016). Deletion of Soluble Epoxide Hydrolase Enhances Coronary Reactive Hyperemia in Isolated Mouse Heart: Role of Oxylipins and PPARgamma. Am J Physiol Regul Integr Comp Physiol, 3(00237).
    
2. Hanif, A., Edin, M. L., Zeldin, D. C., Morisseau, C., & Nayeem, M. A. (2016). Effect of Soluble Epoxide Hydrolase on the Modulation of Coronary Reactive Hyperemia: Role of Oxylipins and PPARgamma. PLoS One, 11(9).
    
3. Hanif, A., Edin, M. L., Zeldin, D. C., Morisseau, C., Falck, J. R., & Nayeem, M. A. (2017). Vascular Endothelial Over-Expression of Human Soluble Epoxide Hydrolase (Tie2-sEH Tr) Attenuates Coronary Reactive Hyperemia in Mice: Role of Oxylipins and omega-Hydroxylases. PLoS One, 12(1).
    
4. Hanif A, Edin ML, Zeldin DC, Morisseau C, Falck JR, Nayeem MA. Vascular endothelial overexpression of human CYP2J2 (Tie2-CYP2J2 Tr) modulates cardiac oxylipin profiles and enhances coronary reactive hyperemia in mice. PLoS One. 2017;12(3):e0174137. Epub 2017/03/23. doi: 10.1371/journal.pone.0174137. PubMed PMID: 28328948.
    
5. Geldenhuys WJ, Hanif A, Yun J, Nayeem MA. Exploring Adenosine Receptor Ligands: Potential Role in the Treatment of Cardiovascular Diseases. Molecules (Basel, Switzerland). 2017;22(6). Epub 2017/06/08. doi: 10.3390/ molecules22060917. PubMed PMID: 28587166.
    
6. Hanif A, Edin ML, Zeldin DC, Morisseau C, Falck JR, Ledent C, et al. Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A2A receptor and plasma oxylipins. Prostaglandins & other lipid mediators. 2017;131:83-95. Epub 2017/09/12. doi: 10.1016/j.prostaglandins.2017.09.001. PubMed PMID: 28890385; PubMed Central PMCID: PMCPMC5635996

2018: "P2 Teacher of the Year" WVU School of Pharmacy               

2016: ASPET Graduate Student Travel Award at Experimental Biology 2016, San Diego, CA, USA

2014: Invited speaker for “12‐Lipoxygenase and Disease: New Insights into Regulation and Inhibition of a Critical Enzyme” symposium organized by the American Society for Pharmacology and Experimental Therapeutics (ASPET) at Experimental Biology 14, San Diego, CA, USA

2014:  ASPET Graduate Student Travel Award at Experimental Biology 2014, San Diego, CA, USA

2014: WVU Graduate Student Travel Award by the Pharmaceutical and Pharmacological Sciences department to attend EB 14, San Diego, CA, USA

2014: WVU Dean's Travel Award to attend EB 14, San Diego, CA

2012: NIH Cardiovascular and Pulmonary Disease Training Grant (NHLBI-T32 Pre-Doctoral training grant) (selected for appointment)

2007: National Association of Boards of Pharmacy (NABP)-certified

Professional teaching

PHAR 814: Biochemical Pharmacology
PHAR 824: Cardiology
PHAR 833: Endocrinology
PHAR 834: Immunology
PHAR 843: Gastroenterology
PHAR 844: Infections Disease

My pharmacy background, teaching experience in the pharmaceutical industry setting, and my training during the graduate program in the Physiology and Pharmacology and the Basic Pharmaceutical Sciences departments make me particularly qualified to teach and effectively reach to PharmD students. I am experienced to teach pharmacology and the related physiology and pathophysiology. At the same time, my thirteen-year experience in pharmaceutical industry’s training and marketing departments both widened my expertise and sharpened my communication and presentation skills to more effectively deliver and interact with my students and peers alike. My research interests include investigating the protective role of augmented CYP epoxygenase-EETs pathway against cardiac ischemia, the associated changes in oxylipins, and the impact of these changes on cardiac functions